BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The grants, approved by the compensation committee, cover a total of 65,500 shares of BioCryst common stock and were issued on April 1, 2025.
The RSUs are structured to vest in four equal annual installments, with the first vesting occurring on the one-year anniversary of the grant date. Vesting is contingent upon continued employment with BioCryst. These equity awards were granted under BioCryst's Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (BCRX) ha concesso unit脿 di azioni vincolate (RSU) a 10 nuovi dipendenti come incentivo all'assunzione. Le concessioni, approvate dal comitato per la retribuzione, coprono un totale di 65.500 azioni di azioni ordinarie di BioCryst e sono state emesse il 1 aprile 2025.
Le RSU sono strutturate per maturare in quattro rate annuali uguali, con la prima maturazione che avverr脿 nel primo anniversario della data di concessione. La maturazione 猫 subordinata al mantenimento dell'impiego presso BioCryst. Questi premi azionari sono stati concessi nell'ambito del Piano di Incentivazione Azionaria di BioCryst e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (BCRX) ha otorgado unidades de acciones restringidas (RSU) a 10 empleados reci茅n contratados como incentivos para la contrataci贸n. Las concesiones, aprobadas por el comit茅 de compensaci贸n, cubren un total de 65,500 acciones de acciones ordinarias de BioCryst y fueron emitidas el 1 de abril de 2025.
Las RSU est谩n estructuradas para adquirirse en cuatro cuotas anuales iguales, con la primera adquisici贸n ocurriendo en el primer aniversario de la fecha de concesi贸n. La adquisici贸n est谩 condicionada a la continuidad del empleo en BioCryst. Estos premios de capital se otorgaron bajo el Plan de Incentivo de Capital de Inducci贸n de BioCryst y cumplen con la Regla de Cotizaci贸n Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (BCRX)電� 10氇呾潣 鞁犼窚 毂勳毄 歆侅洂鞐愱矊 瓿犾毄 鞙犾澑鞙茧 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅鞀惦媹雼�. 氤挫儊 鞙勳洂須岇棎靹� 鞀轨澑霅� 鞚� 攵�鞐姅 齑� 65,500欤�鞚� BioCryst 氤错喌欤茧ゼ 韽暔頃橂┌, 2025雲� 4鞗� 1鞚检棎 氚滍枆霅橃棃鞀惦媹雼�.
搁厂鲍电� 4須岇潣 霃欕摫頃� 鞐瓣皠 頃犽秬搿� 攵勴暊 歆�旮�霅橂弰搿� 甑“頇旊悩鞏� 鞛堨溂氅�, 觳� 氩堨Ц 歆�旮夓潃 攵�鞐澕鞚� 1欤茧厔 旮半厫鞚检棎 氚滌儩頃╇媹雼�. 歆�旮夓潃 BioCryst鞐愳劀鞚� 瓿勳啀鞝侅澑 瓿犾毄鞐� 霐半澕 雼澕歆戨媹雼�. 鞚� 鞛愲掣 氤挫儊鞚� BioCryst鞚� 鞙犾澑 鞛愲掣 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, Nasdaq 靸侅灔 攴滌爼 5635(c)(4)毳� 欷�靾橅暕雼堧嫟.
BioCryst Pharmaceuticals (BCRX) a accord茅 des unit茅s d'actions restreintes (RSU) 脿 10 nouveaux employ茅s en tant qu'incitatifs 脿 l'embauche. Les attributions, approuv茅es par le comit茅 de r茅mun茅ration, couvrent un total de 65 500 actions ordinaires de BioCryst et ont 茅t茅 茅mises le 1er avril 2025.
Les RSU sont structur茅es pour se lib茅rer en quatre versements annuels 茅gaux, le premier versement ayant lieu 脿 la premi猫re date anniversaire de la date d'attribution. La lib茅ration est conditionn茅e 脿 la poursuite de l'emploi chez BioCryst. Ces r茅compenses en actions ont 茅t茅 accord茅es dans le cadre du Plan d'Incitation au Capital de BioCryst et sont conformes 脿 la r猫gle de cotation Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (BCRX) hat 10 neu eingestellten Mitarbeitern als Anreiz zur Besch盲ftigung beschr盲nkte Aktieneinheiten (RSUs) gew盲hrt. Die Vergaben, die vom Verg眉tungsausschuss genehmigt wurden, umfassen insgesamt 65.500 Aktien der Stammaktien von BioCryst und wurden am 1. April 2025 ausgegeben.
Die RSUs sind so strukturiert, dass sie in vier gleichen j盲hrlichen Raten f盲llig werden, wobei die erste F盲lligkeit am ersten Jahrestag des Vergabedatums erfolgt. Die F盲lligkeit ist an die Fortsetzung der Besch盲ftigung bei BioCryst gebunden. Diese Eigenkapitalvergaben wurden im Rahmen des Anreiz-Eigenkapital-Incentive-Plans von BioCryst gew盲hrt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- New employee hiring indicates company growth and expansion
- Potential dilution of existing shareholders through 65,500 new shares
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst鈥檚 board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee鈥檚 continued service with the company. The RSUs are subject to the terms and conditions of BioCryst鈥檚 Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO庐 (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .
BCRXW
Contact:
John Bluth
+1 919 859 7910
FAQ
How many shares of RSUs did BioCryst (BCRX) grant to new employees in April 2025?
What is the vesting schedule for BioCryst's (BCRX) April 2025 RSU grants?
Under which regulatory framework were BioCryst's (BCRX) April 2025 RSUs granted?
How many new employees received RSU grants from BioCryst (BCRX) in April 2025?
